Who are Saw Palmetto - weeks 48 - 72's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zeller Entspannung film coated tablet, BNO 1016, Saw Palmetto - weeks 24 - 48, Passiflora ; Crataegus and Salix, Saw Palmetto - first 24 weeks, Cimicifuga + Hiperico.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/saw-palmetto-weeks-48-72.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Saw Palmetto - weeks 48 - 72 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saw Palmetto - weeks 48 - 72 (Saw Palmetto - weeks 48 - 72) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phytotherapeutic. Area: Urology.

phase 3 Phytotherapeutic Urology Small molecule Live · refreshed every 30 min

Target snapshot

Saw Palmetto - weeks 48 - 72 (Saw Palmetto - weeks 48 - 72) — University of Alabama at Birmingham. Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Saw Palmetto - weeks 48 - 72 TARGET	Saw Palmetto - weeks 48 - 72	University of Alabama at Birmingham	phase 3	Phytotherapeutic
Zeller Entspannung film coated tablet	Zeller Entspannung film coated tablet	Max Zeller Soehne AG	marketed	Herbal preparation / Phytotherapeutic agent
BNO 1016	BNO 1016	Bionorica SE	phase 3	Herbal combination / Phytotherapeutic agent
Saw Palmetto - weeks 24 - 48	Saw Palmetto - weeks 24 - 48	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Passiflora ; Crataegus and Salix	Passiflora ; Crataegus and Salix	Marjan Industria e Comercio ltda	phase 3	Herbal combination / Phytotherapeutic agent
Saw Palmetto - first 24 weeks	Saw Palmetto - first 24 weeks	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Cimicifuga + Hiperico	Cimicifuga + Hiperico	Phytopharm Consulting Brazil	phase 3	Herbal combination / phytotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phytotherapeutic class)

University of Alabama at Birmingham · 3 drugs in this class
VSM Geneesmiddelen b.v. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saw Palmetto - weeks 48 - 72 — Competitive Intelligence Brief. https://druglandscape.com/ci/saw-palmetto-weeks-48-72. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab